NCT01773785 2021-10-13Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary CancerSpectrum Pharmaceuticals, IncPhase 2 Terminated30 enrolled
NCT00868998 2016-05-23GTX Regimen for Biliary CancersColumbia UniversityPhase 2 Terminated4 enrolled 7 charts